Browsing Clinical Studies by author "Clarke, Matthew"
Now showing items 1-9 of 9
-
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George, SL; Izquierdo, E; Campbell, J; Koutroumanidou, E; Proszek, P; et al. (ELSEVIER SCI LTD, 2019-11-01)BACKGROUND: For children with cancer, the clinical integration of precision medicine to enable predictive biomarker-based therapeutic stratification is urgently needed. METHODS: We have developed a hybrid-capture next-generation ... -
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-01)Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ... -
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Zimmermann, M; Murina, O; Reijns, MAM; Agathanggelou, A; Challis, R; et al. (NATURE PUBLISHING GROUP, 2018-07-12)The observation that BRCA1- and BRCA2-deficient cells are sensitive to inhibitors of poly(ADP-ribose) polymerase (PARP) has spurred the development of cancer therapies that use these inhibitors to target deficiencies in ... -
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2020-04-01)The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, ... -
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil, V; Miranda, S; Riisnaes, R; Gurel, B; D'Ambrosio, M; et al. (AMER ASSOC CANCER RESEARCH, 2021-12-15)It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that ... -
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Nava Rodrigues, D; Rescigno, P; Liu, D; Yuan, W; Carreira, S; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2018-10-01)BACKGROUND: Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection. METHODS: Defective mismatch repair (dMMR) status was determined by either loss ... -
Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma.
Zormpas-Petridis, K; Poon, E; Clarke, M; Jerome, NP; Boult, JKR; et al. (AMER ASSOC CANCER RESEARCH, 2020-08-15)Noninvasive early indicators of treatment response are crucial to the successful delivery of precision medicine in children with cancer. Neuroblastoma is a common solid tumor of young children that arises from anomalies ... -
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Boysen, G; Rodrigues, DN; Rescigno, P; Seed, G; Dolling, D; et al. (AMER ASSOC CANCER RESEARCH, 2018-11-15)Purpose: CHD1 deletions and SPOP mutations frequently cooccur in prostate cancer with lower frequencies reported in castration-resistant prostate cancer (CRPC). We monitored CHD1 expression during disease progression and ... -
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.
Thomson, DJ; Cruickshank, C; Baines, H; Banner, R; Beasley, M; et al. (ELSEVIER IRELAND LTD, 2022-11-01)•There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the ...